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Abstract
Background: Interferon-gamma release assays (IGRAs) are increasingly used in the tuberculosis (TB) screening of
health care workers (HCWs). However, comparatively high rates of conversions and reversion as well as growing
evidence of substantial within-subject variability of interferon-gamma responses complicate their interpretation in
the serial testing of HCWs.
Methods: We conducted a systematic review on the repeat use of the two commercial IGRAs, the QuantiFERON-TB
Gold or In-Tube version (QFT) and the T-SPOT.TB (T-SPOT), in the serial testing and its with-subject variability among
HCWs in order to provide guidance on how to interpret serial testing results in the context of the periodic
screening of subjects with an increased occupational risk of latent TB infection (LTBI) in countries with low and
intermediate TB incidence rates. The Medline, Embase, and Cochrane databases were searched without restrictions.
Retrieved articles were complemented by additional hand searched records. Only studies that used commercial
IGRAs among HCWs apart from contact and outbreak investigations and those fulfilling further predefined criteria
were included.
Results: Overall, 20 studies, five using the T-SPOT and 19 using the QFT assay, were included. Fifteen studies met
eligibility criteria for serial testing and five studies for within-subject variability. Irrespective of TB incidence rates in
the study’s country of origin, reversion rates were consistently higher than conversion rates (range 22–71% vs. 1–
14%). Subjects with baseline results around the diagnostic threshold were more likely to show inconsistent results
on retesting. The within-subject variability of interferon-gamma responses was considerable across all studies
systematically assessing it.
Conclusions: On the basis of reviewed studies we advocate using a borderline zone from 0.2–0.7 IU/ml for the
interpretation of repeat QFT results in the routine screening of HCWs with an increased LTBI risk. Subjects with QFT
results within this borderline zone, with suspected fresh infection, and those who are considered for preventive
chemotherapy should be retested with the QFT within a period of about four weeks before preventive
chemotherapy is recommended. However, the available data regarding the use of the T-SPOT in the serial testing of
HCWs is remarkably limited and warrants further research.
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Health care workers (HCWs) may have an increased risk
of occupational tuberculosis (TB) infection due to pos-
sible nosocomial exposure [1-4]. Therefore, exposed
HCWs are subject to periodic TB screening with a view
to identifying infection at an early stage and preventing
the development of active TB by means of preventive
chemotherapy [5,6]. In the absence of clinical evidence
of active TB, latent TB infection (LTBI) is understood
by current consensus to be proven by a Mycobacterium
tuberculosis-specific T-cell-mediated adaptive immune
response, either by a positive tuberculin skin test (TST)
or a positive interferon-γ release assay (IGRA) [7].
However, that does not necessarily have to mean that
live and augmentable mycobacteria exist. In Germany,
section 4 of the regulation on occupational safety and
health (OSH) prescribes regular compulsory screening of
employees in infectious diseases, respiratory medicine,
and in laboratories insofar as they come into regular
contact with people suffering or suspected of suffering
from TB, or possibly coming into contact with infectious
or contaminated material [8]. Usually, these OSH screen-
ings are performed at one-year to three-year intervals. In
addition to identifying LTBI as an irregular physical con-
dition by the terms of OSH legislation, these screenings
are aimed at establishing the rate of new TB infections
as a measure of the effectiveness of the preventive mea-
sures implemented and at reducing the risk of a HCW
to develop active TB, e.g. by prescribing preventive
chemotherapy.
Despite its known limitations, in particular its cross-
reactivity after vaccination with the attenuated Mycobac-
terium bovis live strain of bacillus Calmette-Guérin
(BCG) and infection with nontuberculous mycobacteria,
the TST, which is more than 100 years old, has been the
only way to diagnose LTBI for decades [9,10]. Its use in
serial testing is complicated by sensitization as a result of
repeated use (the so-called “boosting” phenomenon)
[11]. In this respect the two IGRAs, the QuantiFERON-
TB Gold and In-Tube version (QFT) and T-SPOT.TB
(T-SPOT), which have been commercially available for a
number of years, offer distinct advantages. They have
now established as alternatives to the TST [12]. IGRAs
are ex-vivo blood tests that avoid the sensitization of the
immune system to mycobacterial antigens in serial test-
ing (“boosting”). Even among BCG-vaccinated HCWs,
IGRAs have a high specificity and correlate well to the
occupational risk of TB exposure [13-15]. They also possess
certain logistical advantages over the TST in that a second
appointment to read the result is no longer required.
However, IGRAs are also subject to a certain biological
and technical variability. Thus, they must be considered
as dynamic tests [14,16,17]. Different borderline zones
(“gray zones”) have been proposed for defining “genuine”
conversions and reversions in order to improve the inter-
pretation of test results as part of IGRA serial testing
[12,17-21]. As there is no gold standard for diagnosing
LTBI, the definition of an appropriate borderline zone is
challenging and an issue of ongoing scientific debate.
Data on the prediction of active TB after conversion,
reversion, or persistently positive IGRA results may help
to determine these borderline zones, but this data is not
readily available [22].
We performed a systematic review on the repeat use of
commercial IGRAs among HCWs, either in serial testing
studies or in studies on the within-subject variability of
interferon-(IFN)-γ responses (as determined by commer-
cial IGRAs), in order to inform policies and practices
related to the TB serial testing of HCWs in countries
with low and intermediate TB incidence rates.
Methods
Search strategy, study selection, and eligibility
This systematic review was conducted according to the
guidelines of the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) statement
[23]. We searched the Medline, Embase, and Cochrane
databases without restrictions regarding language or
study design though 15 Mar 2012. The following search
string was used: ("Tuberculosis" OR "TB infection")
AND ("interferon-gamma" OR “gamma-interferon” OR
"interferon" OR “interferon-gamma release assay” OR
“IGRA” OR "Quantiferon" OR "T-SPOT") AND ("health
care workers" OR "healthcare workers" OR "health-care
workers" OR "health personnel"). In addition reference
lists, citations of previous reviews, and abstracts from
conference proceedings were hand searched. In case
of doubt authors of original studies were contacted to
obtain additional information. Only original studies (re-
search articles or letters containing original data) among
HCWs or those containing a significant proportion of
HCWs (> 50% of the study population) that were con-
ducted apart from (cross-sectional) LTBI prevalence,
contact tracing, or outbreak investigations and repeatedly
used one of the two or both commercially available
IGRAs on the same group of subjects (at least twice with
the same assay; longitudinal or serial testing design) were
considered eligible. Case reports, case series, comments,
editorials, reviews, cost effectiveness analyses, studies not
following the manufacturers’ instructions (e.g. studies
using prolonged incubation or freezing of cells), and
studies involving less than 10 subjects or any kind of
therapeutic intervention such as treatment for LTBI or
active TB (i.e. studies using an IGRA for the monitoring
of treatment response) were excluded.
For an optimal assessment of the behavior of IGRAs in
serial testing, these studies had to be performed among
HCWs with a low or intermediate occupational TB risk,
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within a TB contact or outbreak investigation, and with a
follow-up for repeat IGRA testing of at least four weeks.
In principle, the same preconditions applied to studies
on the within-subject variability of IFN-γ responses as
determined by commercial IGRAs. The risk of exposure
to TB in the course of the study is particularly important
for the results of any such study. Those studies per-
formed in countries with an intermediate or high inci-
dence of TB should therefore have been conducted over
as short a period as possible (less than four weeks) in
order to avoid conversions due to fresh TB infection.
Furthermore, consistent, well defined, and controlled or
controlled-modified test conditions should have been ap-
plied and additional quality assurance measures should
have been implemented. Studies with subjects who have
had a TST within the past three months were explicitly
excluded due to evidence that a recent TST may influ-
ence IGRA results by the “boosting” of IFN-γ responses.
Apparently, this applies if sensitization to mycobacterial
antigens preexists [20,24,25].
Data extraction, data analysis, and quality assessment
Two reviewers (AS and FCR) independently assessed
articles for eligibility. Disagreement was resolved by con-
sensus. Data extraction was performed using a data ex-
traction form by one reviewer (FCR) and confirmed by
a second reviewer (AS). In serial testing studies the out-
comes of interest were: recruitment period, country and
epidemiological setting of the study according to the
World Health Organization (WHO) [26], IGRA(s) used,
interval(s) between repeat IGRA testing, number of
included subjects, rate of positive results at baseline, rate
of reversions, and rate of conversions. In studies on the
IGRA within-subject variability the outcomes of interest
were: country and epidemiological setting of the study
according to the WHO, IGRA(s) used, number of included
subjects and total number of tests conducted, time points
at which IGRAs were performed, and results with respect
to the observed IGRA within-subject variability.
Weighted mean incidence rates were calculated for rever-
sions and conversions. The completeness of reported out-
come parameters, the reporting of quantitative follow-up
IGRA results stratified according to the quantitative base-
line results, and a prospective study design were considered
as quality indicators. Due to the apparent heterogeneity of
study designs and study quality, time intervals between re-
peat IGRAs, included study populations, epidemiological
settings, and the applied assays, performing pooled analysis
(meta-analysis) was considered inappropriate.
Results
Figure 1 summarizes the process of study selection.
Finally, after excluding two full-text articles that had
been assessed for eligibility in detail [27,28], 20 studies
were included in the review. Of those, 15 studies met
eligibility criteria for the serial testing analysis [17,29-42],
while 5 studies met eligibility criteria for the within-
subject variability analysis [20,21,24,43,44].
Studies on IGRA serial testing
Table 1 provides an overview of publications to date on
the serial testing of HCWs using commercial IGRAs by
the incidence of TB in the study’s country of origin and
summarizes their most important characteristics and
results. Overall, these studies included 6605 subjects. Re-
version rates ranged from 22.1 to 71.4%, while conver-
sion rates ranged from 0.7 to 14.4%. The weighted mean
incidence rate of QFT reversions based on 3849 subjects
from 9 studies from countries with low and intermediate
TB incidence rates [30,33-35,37-40,42] was 33.6% (95%
confidence interval 29.6 – 37.7). The weighted mean in-
cidence rate of QFT conversions based on 6072 subjects
from 12 studies from countries with low and intermedi-
ate TB incidence rates [29,30,32-34,36-42] was 5.1%
(95% confidence interval 4.5 – 5.7). The number of sub-
jects included in the two studies using the T-SPOT assay
was comparatively low (overall 1463 subjects) [31,34].
Only one study reported the reversion rate for the T-
SPOT [34]. Based on their retrospective study design
[35,41] and the incompleteness of data reporting [29,31-
34,36] eight studies were considered to be of minor qual-
ity, while seven studies were considered to be of superior
quality [17,30,37-40,42].
Even though the included serial testing studies differed
substantially in their design and epidemiological setting,
what they all had in common is that inconsistent IGRA
serial testing results (conversions and reversions) oc-
curred fairly frequently and that even in countries with
an intermediate or high incidence of TB, reversions of
positive IGRA results were observed more frequently
than conversions of negative results (Table 1). Moreover,
in studies reporting (stratified) quantitative QFT results,
the likelihood of conversions and reversions of QFT
results increased in subjects with initial test results close
to the diagnostic threshold, generally within a borderline
zone between 0.2 to 0.7 IU/ml [37-42]. However, published
serial testing studies reporting quantitative T-SPOT results
for analysis were unavailable within the searched databases.
Studies on the within-subject variability of the IFN-γ
response
So far, there were only few well-conceived studies that
have investigated the (biological) within-subject variabil-
ity or the influence of technical issues on the reproduci-
bility of the Mycobacterium tuberculosis-specific IFN-γ
response [20,21,24,43,44]. Table 2 summarizes the stud-
ies on the within-subject variability of IFN-γ responses
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bility criteria mentioned above. However, the number of
subjects tested in the available studies was low (overall
219 subjects) and ranged from 14 to 117 subjects. These
studies were carried out almost exclusively on HCWs.
Remarkably, studies from countries with a low incidence
of TB [24,39,44] as well as studies comparing the two
commercially available IGRAs [20,24,44] have rarely
been published. Differences in the statistical assessment
of within-subject variability handicap comparability
(Table 2), but what all the above-mentioned studies had
in common was that the amount of observed within-sub-
ject variability was considerable and, again, that conver-
sions or reversions of IGRA results were more likely to
be found if the initial test result was close to the diagnos-
tic cut-off [20,21,24,43,44].
Discussion
Despite the remarkable amount of publications on the
two commercially available IGRAs, their implementation
in recommendations and guidelines [5,12,45-49], and
their widespread use in daily clinical practice, only a few
studies have been published to date on their use in the
serial testing of HCWs [17,29-42] and on their within-
subject variability [20,21,24,43,44]. Two other recently
published systematic reviews identified a mere ten ori-
ginal studies on serial testing and four on within-subject
variability that corresponded to previously defined
selection criteria and quality indicators [15,25]. The
medical literature available suggests that conversions and
reversions occurring in IGRA serial testing are due to
the considerable biological (within-subject) and technical
variability of the IFN-γ response. The test manufacturers’
dichotomous cut-off values seem to be only partly appro-
priate for the interpretation of repeat IGRA results. A
current review by Zwerling and colleagues on the TB
screening of HCWs using IGRAs found existing data to
be insufficient to make a general recommendation regarding
their use instead of the TST in serial testing [15]. However,
in our own experience, in a country with a low incidence of
TB and a high BCG vaccination coverage the use of an
IGRA instead of the TST may safely reduce the prevalence
of positive test results and thereby the number of HCWs
w h or e q u i r eac h e s tX - r a yt or u l eo u ta c t i v eT B[ 5 0 ] .
Torres Costa and colleagues, who in Portugal carried
out repeat testing of the largest European cohort of
HCWs to date, found a close relation between the IFN-γ
response of initial and follow-up QFT results. QFT
results in a borderline zone between 0.2 and 0.7 IU/ml
had, when the test was repeated, undergone an especially
frequent qualitative change (i.e. a change from a negative
to a positive result and vice versa; 49.0% vs. 8.7% of
subjects with a QFT result of<0.2 or>0.7 IU/ml) [40].
Furthermore, their study also revealed that using a bor-
derline zone between 0.2 und 0.7 IU/ml could reduce
the rate of QFT conversions and reversions significantly
Records identified 
through database 
searching (n = 117)
Additional records 
identified through other 
sources (n = 5)
Records screened 
(n = 123)
Records excluded after 
screening of title and abstract 
(n = 101)
Full-text articles 
assessed for eligibility 
(n = 22)
Articles excluded (n = 2):
short-term follow-up (n = 1),
point source exposure (n = 1)
Unique studies 
included in systematic 
review (n = 20)
Studies on IGRA 
serial testing (n = 15)
Studies on IGRA 
within-subject 
variability (n = 5)
Figure 1 Flow diagram for study selection. Abbreviation: IGRA = interferon-γ release assay.
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to 3.6% and the reversion rate from 22.1% to 5.2%. This
observation is in accordance with the findings of two
current studies of German HCWs by our own working
group. Using this borderline zone, the conversion rates
were reduced from 1.9% to 0.6% and from 6.1% to 2.6%
and the reversion rates from 33.3% to 16.7% and from
32.6% to 15.4%, respectively [37,38]. No cases of active
TB occurred during the follow-up period of more than
two years. In one of the two studies in which 182 HCWs
Table 1 Characteristics and results of studies on serial testing using IGRAs
Study (Year of
publication)
Recruitment
period
Country IGRA(s)
used
Time
between
IGRAs
N* Initially
positive
IGRAs
#(%)
IGRA
reversions
(%)
IGRA
conversions
(%)
Studies in countries with a high incidence of TB (≥ 100 per 100,000 population and year)
Pai et al.
(2006) [17]
2004 India QFT 18 months 216 38/216 (17.6) 9/38 (23.7) 18/178 (10.1)
Studies in countries with an intermediate incidence of TB (≥ 20 and<100 per 100,000 population and year)
Chee et al.
(2009) [31]
2005–2007 Singapore T-SPOT 1 year 182 -
† -
† 9/182 (4.9)
Lee et al.
(2009) [32]
2007 South
Korea
QFT
{ 1 year 169 23/169 (13.6) -** 21/146 (14.4)
Yoshiyama et al.
(2009) [30]
2003, 2005 Japan QFT
{ 2–4 years 311 27/311 (8.7)
†† 13/31
(41.9)
††
6/287 (2.1)
††
Park et al.
(2010) [36]
2008–2009 South
Korea
QFT 1 year 275 29/275 (10.5) -** 14/244 (5.7)
Torres Costa et al.
(2011) [40]
2007–2009 Portugal QFT 1 year 670 208/670
(31.0)
46/208 (22.1) 51/462 (11.0)
Rafiza et al.
(2012) [42]
2009–2010 Malaysia QFT 1 year 769 64/769 (8.3) 19/64 (29.7) 69/704 (9.8)
Studies in countries with a low incidence of TB (< 20 per 100,000 population and year)
Pollock et al.
(2008) [29]
2006 USA QFT
{ 1–7 months 43 -
† -
† 2/43 (4.7)
Zwerling et al.
(2009)
} [33]
2007–2008 Canada QFT 1 year 60 4/60 (6.7) 2/4 (50.0) 4/56 (7.1)
Belknap et al.
(2010)
} [34]
Unknown USA QFT 6 months 1281 50/1281 (3.9) 20/50 (40.0) 44/1169 (3.8 )
T-SPOT 68/1281 (5.3) 36/68 (52.9) 44/1117 (3.9)
Gandra et al.
(2010) [35]
##
2008 USA QFT 4 weeks 135 -
## 66/135 (48.9) -
##
Ringshausen
et al.
(2010) [37]
2005–2008 Germany QFT 18 weeks 182 18/182 (9.9) 6/18 (33.3) 3/162 (1.9)
Schablon et al.
(2010) [38]
2006–2009 Germany QFT 1 year 287 42/287 (14.6) 13/42 (31.0) 15/245 (6.1)
Schablon et al.
(2011) [39]
2008–2009 Germany QFT 1 year 154 2/154 (1.3) 1/2 (50.0) 1/152 (0.7)
Fong et al.
(2012) [41]
}
2007–2010 USA QFT 1 year 1871 -
} 10/14 (71.4)
} 52/1857 (2.8)
* Number of subjects with IGRA test repeats in the course of the study.
# Initially positive IGRA results in the cohort with IGRA test repeats.
† Only subjects with initially negative IGRA results were retested.
{ QuantiFERON-TB Gold.
** Reversion rate not reported.
†† Over the course of the study 139 subjects were retested thrice. Conversion and consecutive reversion occurred in three subjects, while reversion and
consecutive conversion occurred in one subject.
} Published abstract.
## Retrospective chart review. Only subjects with initially positive IGRA results were retested.
} Retrospective chart review. According to the institution’s occupational health policy, health care workers with positive IGRA results were not subject to annual
repeat testing. Retesting of initially IGRA-positives was performed on an individual basis only. Hence, the remainders of the 486 initially QFT-positive subjects (486/
7374; 6.6%) were either advised LTBI therapy, declined retesting, or were lost to follow-up. Of the subjects with IGRA conversions on retesting, ten subjects were
retested for a third time, of whom eight (80%) showed a reversion back to a negative IGRA result.
Abbreviations: IGRA = interferon-γ release assay; QFT = QuantiFERON-TB Gold In-Tube; TB = Tuberculosis; T-SPOT = T-SPOT.TB.
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along with increasing age and the extent of the initial
IFN-γ response, a positive TST both in the past and at
the time of the current evaluation was a significant pre-
dictor of a persistently positive IFN-γ response in serial
testing [37]. These findings have largely been confirmed
by a recent study by Gandra and colleagues in another
low TB incidence country (USA) [35].
In a further recent study of our own we showed that
the within-subject variability of the IFN-γ response of
both IGRAs in middle-aged HCWs (mean 42±10.5 years
old) with a low to intermediate risk of TB exposure over
a period of four weeks was quite considerable [44].
Changes in mean IFN-γ response of about±70% (QFT)
and±60% (T-SPOT) accounted for 95% of the within-sub-
ject variability. With dichotomous interpretation of test
results, inconsistent results occurred with significantly
greater frequency with the QFT (29%) than with the T-
SPOT (9%; p<0.001). The statistical phenomenon of re-
gression towards the means led to a significant reduction
in the mean IFN-γ response of both IGRAs by about
−25% from week to week. Applying borderline zones be-
tween 0.2 to 0.7 IU/ml (QFT) and between 4 to 8 spot-
forming cells (SFCs; T-SPOT) reduced primarily the rate
of QFT reversions (from 50% to 17%). These results are
comparable with those of a South African study in which
changes of±80% (QFT) and±3 SFCs (T-SPOT) were re-
sponsible for 95% of the within-subject variability (Table 2)
[20]. Discordant results for the two IGRAs occurred in a
total of 9% (8/88) of subjects and were thus similar in fre-
quency to our own findings (13%, 20/158 subjects) [20,44].
The three studies conducted in countries with a high TB
incidence (India, South Africa) can only to a limited extent
be compared with studies conducted in TB low incidence
countries (Germany, USA), because they included only a
small number of subjects with IGRA results close to the
diagnostic threshold and had high overall rates of positive
IGRA results of between 40% and 57% and large max-
imum individual variation ranges of the absolute IFN-γ re-
sponse (8.41 to 11.11 IU/ml for the QFT) [20,21,43].
Table 2 Characteristics and results of studies on within-subject variability of the IFN-γ response
Study
(Year of publication)
Country IGRA(s) used Subjects
(total number of tests)
Visits (Days) Summary of results
Studies in countries with a high incidence of TB (≥ 100 per 100,000 population and year)*
Veerapathran et al. (2008) [21] India QFT 14 (56) 0, 3, 9, 12 Over a two-week period, two out of
14 subjects (14%) had a QFT reversion.
Overall, reproducibility of the quantitative
results was moderate. A non-significant
30% reduction in mean IFN-y response
was observed between visits. An increase
of up to 16% in IFN-γ concentration was
within the expected within-subject variability.
Van Zyl-Smit et al. (2009) [20] South Africa QFT T-SPOT 26
# (88) 0, 7, 14, 21 Over a three-week period seven out of
26 volunteers had a conversion or a reversion
(1x QFT, 6x T-SPOT). A change in mean IFN-γ
response of±80% (QFT) or±3 SFCs accounted
for 95% of the within-subject variability.
Detjen et al. (2009) [43] South Africa QFT 27 (54) 0, 3 Over a three-day period no qualitative changes
in the QFT results were noted in 15 subjects,
but a partly substantial within-subject variability
in IFN-γ response was observed
(intra-class correlation=0.80).
Studies in countries with a low incidence of TB (< 20 per 100,000 population and year)
Belknap et al. (2009)
† [24] USA QFT T-SPOT 117 (234) 0, 7–21 Over a three-week period seven out of 117 (6%)
and eight out of 105 (8%) had a conversion
or reversion with QFT or T-SPOT respectively.
Ringshausen et al. (2011) [44] Germany QFT T-SPOT 35 (158) 0, 7, 14, 21, 28 Changes of±70% (QFT) and±60% (T-SPOT) in
mean IFN-γ response accounted for 95% of the
within-subject variability. Inconsistent results
were significantly more frequent with QFT (29%)
than with T-SPOT (9%).
* In studies conducted in countries with a high TB incidence occult TB exposure during the study cannot be ruled out with certainty.
# Health care workers and healthy (“low risk”) subjects.
† Published abstract with updated preliminary results presented by Daley C. (on behalf of the CDC TB Epidemiological Studies Consortium). Evaluation of
Interferon-γ Release Assays in the Diagnosis of Latent TB Infection in U.S. Healthcare Workers: Preliminary Results of Task Order #18. May 31 2009; 2nd Global
Symposium on IGRAs, Dubrovnik, Croatia.
Abbreviations: IGRA = interferon-γ release assay; IFN-γ = interferon-γ; QFT = QuantiFERON-TB Gold In-Tube; SFC = spot-forming cell; TB = tuberculosis;
T-SPOT = T.SPOT.TB.
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the specificity and the negative predictive value of the
QFT among trainee nurses and HCWs. The average age
of study participants was 23±5.8 years. In this cohort
with a very low risk of previous TB exposure there was,
with respect to the qualitative findings, only a low
within-subject variability of IFN-γ responses over a one-
year period. Out of a total of 154 subjects who under-
went a repeat test, two were positive in the first test.
One of the two remained positive in the second test,
whereas the other showed a reversion. Of the 152 trai-
nees who were negative in the first test, 151 had consist-
ently negative QFT results (99%). The one subject with a
conversion showed an increase in IFN-γ concentration
from 0.01 to 0.67 IU/ml. Applying the borderline zone
from 0.2 to 0.7 IU/ml, this increase would not be
counted as a conversion. This individual had no TB in-
fection risk. Overall, the quantitative results were mainly
stable at<0.1 IU/ml and emphasized the high specificity
of the QFT in this young cohort with a low risk of TB
exposure. None of the trainees developed TB during the
two-year observational period, indicating a negative pre-
dictive value of 100% among this population.
In summary, IGRA reversions have been observed
more frequently than conversions in serial testing stud-
ies. A possible explanation for this observation could be
the frequently inevitable statistical phenomenon of re-
gression towards the means, which occurs wherever re-
peat measurements are performed of the same individual
with a random measurement error, i.e. with an unsys-
tematic spread around a true mean [51]. Taking this
phenomenon into account is especially important if sub-
jects are categorized or stratified on the basis of certain
initial measurements, e.g. if the effect of a therapy or the
incidence of a disease is estimated on the basis of repeat
measurements of surrogate parameters. As the effect of re-
gression towards the means increases in proportion to the
variability of the method employed it can be reduced by in-
creasing the number of independent initial measurements,
i.e. by an approximation to the “true” mean. However, this
approach will rarely be applicable in practice. Hence, the
definition of a borderline zone for the interpretation of
serial measurements is an appropriate alternative.
Our review is subject to limitations. The number of eli-
gible and accessible studies as well as their quality and the
number of included subjects were limited. Furthermore,
we did not systematically assess risk factors for conversion,
reversion, or persistent positivity of IGRA responses, which
recently have been reported in detail somewhere else [15].
Finally, it should be emphasized that even a negative
IGRA result can never rule out either active TB or LTBI
with absolute certainty. Moreover, clinical information
on the individual risk of exposure and the susceptibility
to TB along with recent or previous TST or IGRA
results should always be taken into account in the overall
context. The safety of a borderline zone for the interpret-
ation of IGRA serial results with regard to the progres-
sion toward active TB may not be inferred from studies
on within-subject variability because these studies gener-
ally cover a limited follow-up period. Further studies on
large cohorts of HCWs with sufficiently long follow-up
periods of more than two years are required to define
more precisely the prognosis of conversions, reversions,
and persistently positive IGRA results.
Conclusion
So far, the published studies on IGRA serial testing and
on the within-subject variability of the IFN-γ response
TB Antigen  Nil
 0.2 IU/ml
TB Antigen - Nil 
25% of Nil value
Nil   8.0 IU/ml
TB Antigen - Nil
> 0.7 IU/ml
Negative
Indeterminate
Positive
Retest within
4 weeks
Mitogen - Nil < 0.5 IU/ml 
and/or Nil > 8.0 IU/ml
No
Yes
Yes
Yes Yes
No
No
No
No
Yes
Figure 2 Proposed flow chart for the interpretation of repeat QFT results in the serial testing of health care workers in countries with
low or intermediate TB incidence rates. Abbreviations: QFT = QuantiFERON-TB Gold In-Tube; TB = tuberculosis.
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incidence of TB demonstrate convincingly that subjects
with a QFT result in a borderline zone between 0.2 to
0.7 IU/ml are significantly more likely to show an incon-
sistent result on retesting [37-40,42,44]. Furthermore, ap-
plying this borderline zone to the interpretation of QFT
results in the serial testing of German HCWs appears to
be safe because none of the 623 HCWs in our own stud-
ies developed active TB in the follow-up period of more
than two years [37-39]. According to the current litera-
ture, the experience regarding the use of the T-SPOT in
the serial testing and its within-subject variability among
HCWs is remarkably limited. The borderline zone of 4
to 8 SFCs propagated for the T-SPOT and following the
US regulatory authority FDA (5 to 7 SFCs) is based
mainly on a single published study and must be considered
to be not yet sufficiently substantiated by scientific evidence,
especially as the study by van Zyl-Smit et al. covered a fol-
low-up observation period of only six months [20].
Hence, in view of the available data on the within-
subject variability of the IFN-γ response and the use of
IGRAs in the serial testing of HCWs in countries with
low and intermediate incidences of TB, we recommend
using a borderline zone from 0.2 to 0.7 IU/ml for the in-
terpretation of repeat QFT results in routine screening
of HCWs with an increased LTBI risk (Figure 2). Sub-
jects with QFT results within this borderline zone, with
suspected fresh infection due to their risk of TB expo-
sure, and who are considered for preventive chemother-
apy should be retested with the QFT within a period of
about four weeks before preventive chemotherapy is
recommended. If a HCW with a previously positive
IGRA is to be retested in accordance with OSH regula-
tions, repeating the IGRA appears appropriate. Only if re-
peat IGRA testing has demonstrated that the HCW
remains persistently IGRA-positive with accordingly high
IFN-γ responses should they be x-rayed immediately at
their next TB screening in order to rule out active disease.
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